Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib plus UK R3 induction backbone in pediatric relapsed/refractory ALL
2014-001633-84Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of carfilzomib in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoint: Phase 1b primary endpoint. Started Sep 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2014-001633-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001633-84.